LAX.SH
SANOFI INDIA LIMITED·PHARMACEUTICALS 66.37·Pharmaceuticals & Biotechnology Companies
Price
2,831.1
+0.13%52W Range
Market Cap
₹6,520.20 Cr
Traded: ₹4.32 Cr (0.07%) 0.0x
Free Float: ₹837.19 Cr (0.52% of FF traded)
Volume · 60D trend
15.28 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
RS Score
Create a free account to unlock your edge
Scanners, market pulse, FII/DII data, and TradingView charts — free forever
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | -- | -- | -- | -- | +1.0% | -- |
| ROE | -- | -- | -- | -- | -- | -- |
| Return | +2.0% | -8.0% | -10.0% | -48.0% | -- | Decelerating |
| Profit | -- | -- | -- | -- | -25.0% | -- |
Quarterly Results
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | |
|---|---|---|---|---|---|---|---|
| Sales | 515 | 524 | 464 | 511 | 469 | 491 | 515 |
| Expenses | 397 | 404 | 348 | 374 | 370 | 377 | 393 |
| Operating Profit | 118 | 120 | 116 | 137 | 100 | 114 | 122 |
| Other Income | 14 | 2 | 21 | 41 | 77 | 82 | 57 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Depreciation | 10 | 9 | 9 | 9 | 9 | 9 | 9 |
| Profit Before Tax | 122 | 113 | 127 | 169 | 167 | 186 | 169 |
| Tax % | 25.0% | 27.0% | 19.0% | 19.0% | 18.0% | 18.0% | 27.0% |
| Net Profit | 91 | 82 | 103 | 137 | 138 | 152 | 123 |
| Exceptional Items | 8 | 0 | 16 | 38 | 68 | 71 | 42 |
| EPS (Rs) | 39.7 | 35.7 | 44.9 | 59.4 | 59.9 | 66.0 | 53.4 |
| Sales Growth (YoY) | 9.7% | 6.8% | -10.0% | -- | -- | -- | -- |
| Sales Growth (QoQ) | -1.7% | 12.9% | -9.2% | 9.0% | -4.5% | -4.7% | -- |
| OP Growth (YoY) | 18.0% | 5.3% | -4.9% | -- | -- | -- | -- |
| OP Growth (QoQ) | -1.7% | 3.4% | -15.3% | 37.0% | -12.3% | -6.6% | -- |
| Profit Growth (YoY) | 22.0% | 2.0% | 15.0% | -- | -- | -- | -- |
| EPS Growth (YoY) | -33.7% | -45.9% | -16.0% | -- | -- | -- | -- |
| EPS Growth (QoQ) | 11.1% | -20.4% | -24.4% | -0.8% | -9.3% | 23.6% | -- |
| OP Margin | 22.9% | 22.9% | 25.0% | 26.8% | 21.3% | 23.2% | 23.7% |
| Net Margin | 17.7% | 15.7% | 22.2% | 26.8% | 29.4% | 31.0% | 23.9% |
| Material Cost % | 48.5% | 49.6% | 47.7% | 48.6% | 46.8% | 48.7% | 49.8% |
| Employee Cost % | 10.4% | 10.8% | 13.0% | 13.6% | 15.4% | 14.6% | 13.6% |
| P/S | 3.24 | -- | -- | -- | -- | -- | -- |
| P/E | 15.75 | -- | -- | -- | -- | -- | -- |
| P/B | 7.57 | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2026 ,inter alia, to consider and approve the Unaudited Financial Results ....
Kindly refer the attachment.
The Exchange has received the disclosure under Regulation 10(7) in respect of acquisition under Regulation 10(1)(a)(iii)of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, ....
Kindly refer the attachment.
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sanofi Healthcare India Pvt Ltd
Kindly refer the attachment
The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, ....
Kindly refer the attachment
Kindly refer the attachment
Kindly refer the attachment
Kindly refer the attachment
Kindly refer the attachment.
Kindly refer the attachment
Kindly refer the attachment
Kindly refer the attachment
Kindly refer the attachment
Kindly refer the attachment
Kindly refer the attachment
Kindly refer the attachment.
Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/08/2026 ,inter alia, to consider and approve the Unaudited Financial Results ....
Please find enclosed certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th June 2026.
Please find enclosed disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Kindly refer the attachment
Please find enclosed disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Please find enclosed disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Please find enclosed intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Please find enclosed copies of the Newspaper publication regarding the information on special window for transfer and dematerialisation of physical shares.
Please find enclosed Press Release dated 30th April 2026
Please find enclosed copies of the Newspaper Publication of Financial Results for quarter ended 31st March 2026, as published in Business Standard (English) and Sakal (Marathi) today i.e. ....
Please find enclosed proceedings of 70th Annual General Meeting.
Please find enclosed Scrutinizers Report on 70th Annual General Meeting.
Please find enclosed a copy of Unaudited Financial Results for the quarter ended 31st March 2026
Press Release dated 28th April 2026 enclosed.
Please find enclosed a copy of the Unaudited Financial Results for the Quarter ended 31st March 2026
Kindly refer the attachment.
Kindy refer the attachment
Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/04/2026 ,inter alia, to consider and approve the Unaudited Financial Results ....
MUFG Intime India Private Limited (formerly known as Link Intime India Private Limited), Registrar and Share Transfer Agent (RTA) of the Company has provided the enclosed certificate for ....
Please find enclosed copies of Newspaper publications.
Please refer the attachment
Please refer the attachment
Please refer the attachment
Please refer the attachment
Please refer the attachment
Please refer the attachment
Please find enclosed Newspaper Advertisement regarding 70th Annual General Meeting and Opening of another Special Window for re-lodgement of transfer requests of physical shares.
Please find enclosed intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Please refer the attachment
Please refer the attachment
Please refer the attachment
Annual Reports
15Concalls
12Mar 2026
31 Mar 2026Nov 2025
30 Nov 2025May 2024
31 May 2024Feb 2024
29 Feb 2024Feb 2024
29 Feb 2024Nov 2023
30 Nov 2023Nov 2023
30 Nov 2023May 2023
31 May 2023May 2023
31 May 2023Feb 2023
28 Feb 2023Feb 2023
28 Feb 2023Mar 2021
31 Mar 2021Held by ETFs
1 ETFs hold sanofi · sorted by weight
Held by Mutual Funds
16 schemes hold sanofi · sorted by weight